Dianthus Therapeutics (DNTH) Gains from Sales and Divestitures (2018 - 2023)
Dianthus Therapeutics (DNTH) recorded quarterly Gains from Sales and Divestitures of $6495.0 in Q4 2023, up 117.3% quarter-over-quarter from $2989.0 in Q3 2023.
Dianthus Therapeutics (DNTH) Gains from Sales and Divestitures (2018 - 2023) Analysis & Trends
Dianthus Therapeutics' Gains from Sales and Divestitures history runs 2 years deep, the most recent figure standing at $6495.0 for Q4 2023.
- In Q4 2023, Gains from Sales and Divestitures changed N/A year-over-year to $6495.0; the TTM figure through Dec 2023 stood at $6495.0 (changed N/A YoY), while the FY2023 annual figure was $6495.0, changed N/A from the prior year.
- Gains from Sales and Divestitures was $6495.0 for Q4 2023 at Dianthus Therapeutics, up from $2989.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $6495.0 in Q4 2023 to a low of $2989.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Dianthus Therapeutics | 3.60 Bn | 3.19 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 6,495.00 |
| Dec 31, 2023 | 6,495.00 |
| Sep 30, 2023 | 2,989.00 |
| Sep 30, 2023 | 2,989.00 |
| Dec 31, 2018 | 907,562.00 |
| Dec 31, 2018 | 907,562.00 |